IRCT20240803062623N12 IRCT 2025-02-21 Tadbir Kala Jam Bioequivalence study of two Mexiletine 200 mg capsule manufactured by Tadbir Kalaye Jam company Bioequivalence study of Mexiletine 200 mg capsule manufactured by Tadbir Kalaye Jam company in comparison with Mexiletine® 200 mg capsule ANNORA PHARMA PRIVATE LTD on healthy volunteers 2025-03-21 anticipated 24 Recruiting https://irct.ir/trial/81488 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: People are checked for health and healthy volunteers are identified. Each candidate is assigned a number from 1 to 24 using a randomization software. Even numbers will receive the reference and odd numbers will receive the test drug in the first period, Blinding description: This study is a single-blinded clinical trial (volunteers). Test and Originator brand's tablets are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test dosage form. Bioequivalence In this study the , the disease is not investigated , bioequivalence of test and brand drug will be evaluated.. Intervention 1: Intervention group: Single-dose of the test drug Mexiletine 200 mg capsule manufactured by Tadbir Kalaye Jam company. Intervention 2: Control group: Single-dose of the reference drug Mexiletine® 200 mg capsule ANNORA PHARMA PRIVATE LTD in the first period. No - There is not a plan to make this available Justification or reason for not sharing IPD is These data are as secure between researchers and related industries.